Similar articles

Abstract: Objective: To evaluate the effect of anti-vascular endothelial growth factor (VEGF) on juxtafoveal choroidal neovascularization (CNV) secondary to multifocal choroiditis (MFC) and wet age-related macular degeneration (AMD). Methods: In this retrospective, comparative study, 20 unique eyes with CNV were divided into two groups: 10 patients affected by MFC and 10 patients diagnosed with wet AMD. They all received local intravitreal (IVT) injections of ranibizumab, with 6 months of follow-up. Retreatment injections were performed based on findings suggestive of active neovascularization. Results: Significant improvements were observed in the juxtafoveal CNV lesions, and average central macular thickness decreased in both groups following the anti-VEGF therapy (P<0.05). The average number of injections used in MFC patients was 1.6, while three injections on average were used in wet AMD patients (Z=−2.844, P=0.009). Best-corrected visual acuity was significantly improved in MFC patients after anti-VEGF therapy (P<0.05), and there was no significant difference in wet AMD patients between before anti-VEGF therapy and 6 months later (P>0.05). Conclusions: IVT ranibizumab resulted in good clinical outcomes for juxtafoveal CNV secondary to MFC and wet AMD, but the average number of injections used in MFC was fewer than that used in wet AMD over a 6-month observation period. Compared with the wet AMD group, visual acuity was obviously improved in the MFC group at 6 months.

抗VEGF药物在多灶性脉络膜炎和湿性老年性黄斑变性中的疗效观察和比较

[1]Alexandru MR, Alexandra NM, 2016. Wet age related macular degeneration management and follow-up. Rom J Ophthalmol, 60(1):9-13.

[2]Cheung CM, Wong TY, 2011. Ranibizumab and bevacizumab for AMD. N Engl J Med, 365(23):2237.

[3]D'Ambrosio E, Tortorella P, Iannetti L, 2014. Management of uveitis-related choroidal neovascularization: from the pathogenesis to the therapy. J Ophthalmol, 2014:450428.

[4]Dardabounis D, Panos GD, 2013. Intravitreal ranibizumab in choroidal neovascularisation due to multifocal choroiditis and panuveitis syndrome. BMJ Case Rep, 2013: bcr2013009572

[5]Dunlop AA, Cree IA, Hague S, et al., 1998. Multifocal choroiditis: clinicopathologic correlation. Arch Ophthalmol, 116(6):801-803.

[6]Fine HF, Zhitomirsky I, Freund KB, et al., 2009. Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis. Retina, 29(1): 8-12.

[7]Flaxel CJ, Owens SL, Mulholland B, et al., 1998. The use of corticosteroids for choroidal neovascularisation in young patients. Eye, 12:266-272.

[8]Gerth C, Spital G, Lommatzsch A, et al., 2006. Photodynamic therapy for choroidal neovascularization in patients with multifocal choroiditis and panuveitis. Eur J Ophthalmol, 16(1):111-118.

[9]Gulati N, Forooghian F, Lieberman R, et al., 2011. Vascular endothelial growth factor inhibition in uveitis: a systematic review. Br J Ophthalmol, 95(2):162-165.

[10]Haen SP, Spaide RF, 2008. Fundus autofluorescence in multifocal choroiditis and panuveitis. Am J Ophthalmol, 145(5):847-853.

[11]Hochman MA, Weiter JJ, Fleckner MR, et al., 1999. Surgical management of choroidal neovascular membranes. Int Ophthalmol Clin, 39:303-315.

[12]Iannetti L, Paroli MP, Fabiani C, et al., 2013. Effects of intravitreal bevacizumab on inflammatory choroidal neovascular membrane. Eur J Ophthalmol, 23(1):114-118.

[13]Julián K, Terrada C, Fardeau C, et al., 2011. Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: long-term results. Acta Ophthalmol, 89(2):179-184.

[14]Jutley G, Jutley G, Tah V, et al., 2011. Treating peripapillary choroidal neovascular membranes: a review of the evidence. Eye, 25(6):675-681.

[15]Kuo IC, Cunningham ET, 2000. Ocular neovascularization in patients with uveitis. Int Ophthalmol Clin, 40(2):111-126.

[16]Kwak N, Okamoto N, Wood JM, et al., 2000. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci, 41(10):3158-3164.

[17]Lim LS, Mitchell P, Seddon JM, et al., 2012. Age-related macular degeneration. Lancet, 379(9827):1728-1738.

[18]Miller DG, Singerman LJ, 2006. Vision loss in younger patients: a review of choroidal neovascularization. Optom Vis Sci, 83(5):316-325.

[19]Perentes Y, Chan CC, Bovey E, et al., 2002. Massive vascular endothelium growth factor (VEGF) expression in Eales’ disease. Klin Monbl Augenheilkd, 219(4):311-314.

[20]Rouvas A, Petrou P, Douvali M, et al., 2011. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Retina, 31:871-879.

[21]Shimada H, Yuzawa M, Hirose T, et al., 2008. Pathological findings of multifocal choroiditis with panuveitis and punctate inner choroidopathy. Jpn J Ophthalmol, 52(4): 282-288.

[22]Spaide RF, Freund KB, Slakter J, et al., 2002. Treatment of subfoveal choroidal neovascularization associated with multifocal choroiditis and panuveitis with photodynamic therapy. Retina, 22(5):545-554.

[23]Starita C, Patel M, Katz B, et al., 2007. Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. Diabetic Retinopathy, 39:122-148.

[24]Thomas MA, Dickinson JD, Melberg NS, et al., 1994. Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology, 101:1384-1396.

[25]Thurau S, Wildner G, 2010. Choroidtis. Ophthalmologe, 107: 79-91 (in German).

[26]Tsutsumi-Miyahara C, Sonoda KH, Egashira K, et al., 2004. The relative contributions of each subset of ocular infiltrated cells in experimental choroidal neovascularisation. Br J Ophthalmol, 88(9):1217-1222.